Pharma business news, market intelligence, and CEO-level case studies
Latest Pharma Intelligence
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9…
Witfire Desk
New reports, regulatory signals, deal autopsies and market consequence analysis from the Witfire desk.
Jun 30, 2026
Viridian’s Lumvoa Broke Tepezza’s Monopoly. Now Viridian Has to Prove It Can Sell | Witfire Elite View Witfire Elite Competitive Strategy Case…
Jun 29, 2026
Sobi NASP CRL: FDA Rejected the Control System | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Manufacturing Long Read…
Jun 24, 2026
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 | Witfire Elite View Witfire Elite Competitive Strategy Case Studies Japan Pharma Long…
Jun 21, 2026
Revolution Medicines Daraxonrasib: The $4.3B Autopsy | Witfire Elite View Witfire Elite Oncology Strategy Case Studies Financing Long Read Pharma Market Case…
Jun 19, 2026
Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy…
Jun 16, 2026
GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite Oncology M&A Case Studies…
Witfire Desk
FDA decisions, CRLs, advisory committee signals, CMC issues and launch-risk interpretation.
Jun 14, 2026
FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy…
Jun 8, 2026
FTX-6058 and Pociredir: FDA’s PRC2 Risk View Hit a Promising Sickle Cell Drug | Witfire Elite View Witfire Elite FDA & Regulatory…
Jun 6, 2026
IQVIA Signal: Wegovy Pill May Expand the GLP-1 Market, Not Just Replace Injections | Witfire Elite View Witfire Elite Pharma Markets Case…
Jun 6, 2026
FDA’s Digital Liver Break: How AI Toxicology Could Change Drug Development Before Phase I | Witfire Elite View Witfire Elite FDA &…
Witfire Desk
Deal, launch, market-share and strategic consequence analysis.
Jun 14, 2026
India CRO Boom: Why Chinese Molecules May Build the Next Outsourcing Wave | Witfire Elite View Witfire Elite Pharma Markets Case Studies…
Jun 13, 2026
Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy…
Jun 12, 2026
Novo Nordisk did not lose momentum because CagriSema is a weak drug. That is too simple. The sharper problem is that CagriSema…
Jun 12, 2026
Witfire Elite View · Pharma Market Case Study · Updated 12 June 2026 The cheapest semaglutide in the world is made in…
Witfire Desk
Pharma valuation, financing, licensing, stock-market exposure and policy-risk movement.
Jun 10, 2026
Eli Lilly Retatrutide Phase 3: 28.3% Weight Loss Pushes Obesity Into a Portfolio War | Witfire Elite View Witfire Elite Pharma News…
Jun 7, 2026
Lilly’s Germany Investment Cut: Why Pharma Capital Is Starting to Vote Against Policy Risk | Witfire Elite View Witfire Elite Investment Case…
Jun 5, 2026
The Pharma Tariff War: How US Drug Pricing Pressure Is Forcing Big Pharma to Rewrite Global Strategy | Witfire Elite View Witfire…
Jul 19, 2025
The US-Israel-Iran war is affecting pharma stocks, drug supply chains, logistics costs, cold-chain movement, and investor sentiment as oil and freight costs…
Witfire Desk
India, Philippines, Asia and emerging healthcare market developments.
Jun 6, 2026
Philippines AI Liver Cancer Breakthrough: How the CANDLE Study Could Change Early Detection | Witfire Elite View Witfire Elite Philippines Pharma Watch…
Decision Table
A fast index of recent pharma events, categories and business consequences.
| Date | Signal | Category | Read |
|---|---|---|---|
| IQVIA Wegovy Pill Data and Oral GLP-1 Market Expansion | Pharma Market Case Studies, Pharma News | Open | |
| Fulcrum’s Pociredir Collapse: How FDA’s PRC2 Risk View Crushed a Data-Rich Sickle Cell Drug | Pharma Market Case Studies, Pharma News | Open | |
| The China Biotech Pipeline Grab: How Big Pharma Started Buying Innovation From China | Pharma Market Case Studies, Pharma News | Open | |
| How GLP-1 Became Pharma’s Most Powerful Growth Story | Pharma News, Startups | Open | |
| GLP-1 Market Becomes Pharma’s Biggest Business Battle | Pharma News | Open | |
| War Heat Reaches Pharma as Oil, Air Cargo and Cold-Chain Drugs Face Pressure | Pharma News | Open | |
| Pharma Stock Market News: US-Israel-Iran War Impact on Drug Supply Chains, Oil Prices and Healthcare Stocks | Stock Market | Open | |
| Data That Shows Why Pharma Business Is Becoming Bigger and More Serious | Pharma News | Open |
Every Witfire report is source-backed and written for the business consequence, not the headline.
Browse all pharma intelligence
Flagship Product
Five intelligence-led analyses on how FDA decisions, geopolitical chokepoints, and policy shifts are repricing global pharma.
Read Witfire magazineTrust Layer
A visible trust system for pharma readers, investors, founders, researchers and media platforms.
For regulatory milestones, funding, CEO features, product launches and scientific announcements.
Open contact pageSponsored content, media partnerships and native advertising need clear labeling and claim support.
Read policyA clear correction route strengthens publisher trust with readers and platforms.
Request correction